Figure 1: Preoperative view of the giant mass
Figure 3: 3a: Surgical area after removal of the mass; 3b: Postoperative view of the giant mass
The patient was administered 4 cycles of doxorubicin (50 mg) and ifosfamide (4 g) chemotherapy in the second postoperative month. In order to increase local control following chemotherapy, radiotherapy with a total of 28 fractions (50.4 Gy) and fractional doses of 1.8 Gy was applied using a Siemens Artiste Linear Accelerator Device (Siemens Medical Solutions, Concord, CA, USA) with 6 MV photon energy. No recurrence was detected in the follow-up PET scan (F-18 FDG) obtained at the postoperative 18th month.
Case-2
A 58-year-old male patient was admitted to our outpatient
clinic with a painless left hemiscrotal mass that has been
growing for about a year. On physical examination, a 12 cmmass
filling the left hemiscrotum was palpated and normal
testicular tissue could be partially palpated next to the mass.
The patient"s preoperative levels of AFP (2.82 ng/mL), β-hCG
(<1.20 ng/mL), and LDH (250 ng/mL) were as indicated. MRI
revealed a mass in the left hemiscrotum that completely filled
the scrotum (Figures 5a,b, and c). It has widest dimensions of
12x7.7x7.6 cm and demonstrated heterogeneous necrotic areas
in T1 hypo T2-weighted series. Heterogeneous opacifications in
post-contrast series, increased diffusion and diffusion restriction
in some places were observed. No signs of metastasis were
observed. Radical orchiectomy was performed through a right
inguinal incision (Figure 6). Pathological examination revealed
a solid lesion weighing 1440 g and having dimensions of a
14x13x6.5 cm adjacent to but not involving the testicle. The
capsule of the lesion was enveloped with typical testicular tissue.
Negative surgical margins were obtained. Pathology report
suggested a well differentiated liposarcoma. Focal positive
nuclear staining was observed with immunohistochemically
applied CDK4, but not with MDM2. It also stained positively
for S100 protein (Figures 7a, and b). The patient was also
evaluated by medical oncology due to the possibility of need for
additional postoperative treatment. No additional treatment was
recommended. No residual tumor or metastases were detected in
the patient's postoperative 3rd month follow-up with PET scan
(F-18 FDG).
Figure 5: 5abc: Sagittal, coronal and axial section view of the giant scrotal mass in MRI
When the tumor diameter exceeds 10 cm, it is called a giant PLS [3]. They manifest as large scrotal mass lesions appearing just below the superficial inguinal ring [7]. Generally, these masses are misdiagnosed as hydrocele, epididymal cyst, inguinal hernia, hematocele or lipoma [9]. On ultrasonography (US), PLSs appear as heterogeneous, solid, hypoechoic lesions with relatively low vascularity, and sometimes liquefaction may accompany if necrosis is present [5,7]. However, US cannot always distinguish PLS from lipomas if the tumor is small or if it is a well-differentiated PLS with a homogeneous fat pattern [11]. Paratesticular liposarcomas are usually seen as heterogeneous mass lesions compatible with fat density in contrast-enhanced CT images. Contrast-enhanced CT can also provide important information regarding staging and follow-up [6]. Another useful imaging technique is MRI, which is the gold standard in the staging of soft tissue tumors. It does not only provide precise information about tumor foci, but also characterizes and defines the extent of local tumor spread [12].
Our Case 1 came with more than one screening examination (CT, MRI and PET) applied in another center before consulting to us. However, our Case 2 applied directly to us. We preferred MRI as preoperative imaging, primarily because of its superiority over the other imaging techniques in demonstrating the surgical site and surrounding soft tissues. On the same day, we made the surgical decision without wasting time in line with the accelerated reports submitted to us by the radiology physicians. In our opinion, it may be more appropriate to use other imaging methods (CT or PET scan) in the postoperative follow-up of metastases. Diagnosis of PLS is mainly made based on the histopathological, immunohistochemical and cytomorphological features of the mass lesion.
When a diagnosis of PLS is suspected, an urgent radical procedure must be performed to avoid the high risk of local recurrence and worsening of the prognosis. The gold standard in PLS treatment is radical orchiectomy with high ligation of the spermatic cord. Wide excision and hemiscrotectomy can also be performed in cases where the mass is larger and local invasion is suspected [13]. The issue of lymph node dissection is controversial. There is not enough data to show that superficial inguinal or retroperitoneal lymph node dissection has any therapeutic efficacy [6]. However, some studies have suggested the application of lymphadenectomy limited to the radiologically detected suspicious lymph nodes [14]. Surgical margin positivity is a risk factor for early recurrence and distant metastases [15]. A clinical study showed that 3-year local recurrence-free survival rates were 100%, and 29% in cases with negative, and positive surgical margins, respectively.
Generally, since liposarcomas are the most radiosensitive types of the sarcomas, radiotherapy is used for local control. In some cases of liposarcomas, remission has been achieved with radiotherapy alone, but the results in PLS are not yet clear. If surgical margin positivity is observed after surgical resection or if there is evidence of a tumor showing a high grade and aggressive behavior, adjuvant radiotherapy may be applied to the inguinal region and scrotum in addition to surgery to prevent local recurrence [16]. Recurrence may occur after radiotherapy in dedifferentiated aggressive tumors. Data on the effectiveness of chemotherapy in metastatic PLS are limited. However, some recent studies have recommended the use of doxorubicin, vincristine and cyclophosphamide [15]. Although the place and effectiveness of adjuvant therapies in the treatment of scrotal liposarcoma are controversial, our first case is one of the largest scrotal liposarcoma cases in the literature, which led us to apply adjuvant therapy more aggressively. However, further studies are needed to define a standard treatment in this regard. With the information we have, application of this type of specific treatment was decided for the patient.
It is important to inform young patients about sperm preservation before orchidectomy. The patient should be informed of the possibility of the presence of dysfunctional testicular tissue remaining after orchiectomy. Apart from this, the information that potential use of adjuvant chemotherapy, and radiotherapy in case of need may adversely affect fertilization, should be shared with the patient. Although long-term infertility after radiotherapy is rarely observed in studies on testicular tumors, it has been found that chemotherapy may cause longterm infertility in a dose-dependent manner. Therefore, the patients who cannot preoperatively preserve their sperms, should be informed about this adverse outcome of chemotherapy before application of adjuvant treatments [17].
In our study, two PLSs were successfully treated and the patients were cured. However, the short postoperative follow-up period of our patients stands out as a limitation of our study. In order to contribute more precise information to the literature, meta-analyses of the cases with longer follow-up periods cited in the literature should be conducted.
Ethics Committee Approval: N / A.
Informed Consent: An informed consent was obtained from the patient.
Publication: The results of the study were not published in full or in part in form of abstracts.
Peer-review: Externally and internally peer-reviewed.
Authorship Contributions: Any contribution was not made by any individual not listed as an author. Concept - E.A., H.G.K.; Design - E.A., H.G.K.; Supervision - E.A., H.E.; Resources - G.S., T.O., A.K., C.T.; Materials - G.S., T.O., A.K., C.T.; Data Collection and/or Processing - G.S., T.O., A.K., C.T.; Analysis and/or Interpretation - E.A., H.G.K., H.E.; Literature Search - G.S., T.O., A.K., C.T.; Writing Manuscript - E.A., H.G.K.; Critical Review - E.A., H.E.
Conflict of Interest: The authors declare that they have no conflict of interest.
Financial Disclosure: The authors declare that this study received no financial support.
1) Chiodini S, Luciani LG, Cai T, Molinari A, Morelli L,
Cantaloni C, et al. Unusual case of locally advanced and
metastatic paratesticular liposarcoma: a case report and
review of the literature. Arch Ital Urol Androl 2015;87:87-9.
https://doi.org/10.4081/aiua.2015.1.87.
2) Noguchi H, Naomoto Y, Haisa M, Yamatsuji T, Shigemitsu
K, Uetsuka H, et al. Retroperitoneal liposarcoma presenting
a indirect inguinal hernia. Acta Med Okayama 2001;55:
51-4.
https://doi.org/10.18926/AMO/32032.
3) Kin T, Kitsukawa S, Shishido T, Maeda Y, Izutani T,
Yonese J, et al. Two cases of giant testicular tumor with
widespread extension to the spermatic cord: usefulness
of upfront chemotherapy (In Japanese). Hinyokika Kiyo
1999;45:191-4.
https://pubmed.ncbi.nlm.nih.gov/10331173/.
4) Kamitani R, Matsumoto K, Takeda T, Mizuno R, Oya M.
Optimal treatment strategy for paratesticular liposarcoma:
retrospective analysis of 265 reported cases. Int J Clin
Oncol 2020;25:2099-106.
https://doi.org/10.1007/s10147-020-01753-3.
5) Li Z, Zhou L, Zhao L, Chen P, Liu Y, Ding Y, et al. Giant
paratesticular liposarcoma: a case report and review of the
literature. Mol Clin Oncol 2018;8:613-6.
https://doi.org/10.3892/mco.2018.1577.
6) Alyousef H, Osman EM, Gomha MA. Paratesticular
Liposarcoma: A Case Report and Review of the Literature.
Case Rep Urol 2013;2013:806289.
https://doi.org/10.1155/2013/806289.
7) Patel NG, Rajagopalan A, Shrotri NS. Scrotal liposarcoma–
a rare extratesticular tumour. JRSM Short Rep 2011;2:93.
https://doi.org/10.1258/shorts.2011.011064.
8) Fitzgerald S, Maclennan GT. Paratesticular liposarcoma. J
Urol 2009;181:331-2.
https://www.auajournals.org/doi/10.1016/j.juro.2008.10.080.
9) Salas-Parra RD, Tavares LL, Gupta R, Silletti J, Shah A.
Dedifferentiated liposarcoma of the scrotum. Case report
and literature review. J Surg Case Rep 2020;2020:rjaa342.
https://doi.org/10.1093/jscr/rjaa342.
10) Fiore M, Grosso F, Lo Vullo S, Pennacchioli E, Stacchiotti
S, Ferrari A, et al. Myxoid/round cell and pleomorphic
liposarcomas: prognostic factors and survival in a
series of patients treated at a single institution. Cancer
2007;109:2522-31.
https://doi.org/10.1002/cncr.22720.
11) Raza M, Vinay HG, Ali M, Siddesh G. Bilateral para
testicular liposarcoma‑a rare case report. J Surg Tech Case
Rep 2014;6:15‑7.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090974/.
12) Vukmirović F, Zejnilović N, Ivović J. Liposarcoma of the
paratesticular tissue and spermatic cord: a case report.
Vojnosanit Pregl 2013;70:693-6.
https://doi.org/10.2298/vsp1307695v.
13) Vorstman B, Block NL, Politano VA. The management of
spermatic cord liposarcomas. J Urol 1984;131:66-9.
https://pubmed.ncbi.nlm.nih.gov/6690750/.
14) Khoubehi B, Mishra V, Ali M, Motiwala H, Karim O.
Adult paratesticular tumours. BJU Int 2002; 90:707-15.
https://doi.org/10.1046/j.1464-410x.2002.02992.x.
15) Rodriguez D, Olumi AF. Management of spermatic cord
tumours: a rare urologic malignancy. Ther Adv Urol
2012;4:325-34.
https://doi.org/10.1177/1756287212447839.